e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
CXCL12 as a potential disease marker for pulmonary hypertension
B. McCullagh, C. Costello, S. Gaine, P. McLoughlin (Dublin, Ireland)
Source:
Annual Congress 2010 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
E-Communication Session
Number:
3513
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. McCullagh, C. Costello, S. Gaine, P. McLoughlin (Dublin, Ireland). CXCL12 as a potential disease marker for pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 3513
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Potential association between pulmonary hypertension in COPD and monocyte chemoattractant protein (MCP)-1
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 425s
Year: 2006
How to detect disease progression in pulmonary arterial hypertension
Source: Eur Respir Rev 2012; 21: 40-47
Year: 2012
Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease
Source: Eur Respir J, 55 (3) 1900169; 10.1183/13993003.00169-2019
Year: 2020
Determinants and prognostic value of kidney disease in pulmonary arterial hypertension
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018
Biomarkers in pulmonary hypertension associated to interstitial lung disease
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?
Source: Eur Respir J 2014; 44: 842-845
Year: 2014
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007
Towards prognostic biomarkers in pulmonary arterial hypertension
Source: Eur Respir J 2012; 39: 799-801
Year: 2012
The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Predictive factors of endothelial function in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Prognosis in COPD
Year: 2008
Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
Pulmonary hypertension in sickle cell disease
Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease
Year: 2007
Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
The link between systemic inflammation and pulmonary hypertension in patients with stable COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 53s
Year: 2005
Hepatic function markers in COPD as a systemic implication of the disease
Source: Annual Congress 2008 - Functionality and metabolism in rehabilitation candidates
Year: 2008
Prognostic value of right ventricular function in patients with severe pulmonary hypertension associated with respiratory disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive lung disease?
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept